|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400091498 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-29 16:23:44 |
|
注册时间: Date of Registration: |
2024-10-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
艾司氯胺酮对非体外循环冠脉旁路移植手术患者术后炎症反应和谵妄的影响 |
|
Public title: |
Effect of esketamine on postoperative inflammatory response and delirium in patients undergoing off-pump coronary artery bypass transplantation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
艾司氯胺酮对非体外循环冠脉旁路移植手术患者术后炎症反应和谵妄的影响 |
|
Scientific title: |
Effect of esketamine on postoperative inflammatory response and delirium in patients undergoing off-pump coronary artery bypass transplantation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
鞠良雨 |
研究负责人: |
刘爱杰 |
|
Applicant: |
Liangyu Ju |
Study leader: |
Aijie Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 178 5423 0118 |
研究负责人电话:
Study leader's |
+86 186 6180 1683 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
15263131072@163.com |
研究负责人电子邮件: Study leader's E-mail: |
13695425836@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省青岛市崂山区海尔路59号 |
研究负责人通讯地址: |
山东省青岛市崂山区海尔路59号 |
|
Applicant address: |
59 Haier Road,Laoshan District,Qingdao City,Shandong Province,China |
Study leader's address: |
59 Haier Road,Laoshan District,Qingdao City,Shandong Province,China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
青岛大学附属医院 |
||
|
Applicant's institution: |
The Affiliated Hospital of Qingdao University |
||
|
研究负责人所在单位: |
青岛大学附属医院 |
||
|
Affiliation of the Leader: |
The Affiliated Hospital of Qingdao University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
QYFYEC2024-141 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
青岛大学附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Affiliated Hospital of Qingdao University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-17 00:00:00 | ||
|
伦理委员会联系人: |
朱婕 |
||
|
Contact Name of the ethic committee: |
Jie Zhu |
||
|
伦理委员会联系地址: |
山东省青岛市市南区江苏路16号 |
||
|
Contact Address of the ethic committee: |
No16, Jiangsu Road, Shinan District, Qingdao City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 5328291869 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
青岛大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Hospital of Qingdao University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省青岛市崂山区海尔路59号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
59 Haier Road,Laoshan District,Qingdao City,Shandong Province,China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
课题组 |
||||||||||||||||||||||
|
Source(s) of funding: |
Research Group |
||||||||||||||||||||||
|
研究疾病: |
冠状动脉粥样硬化性心脏病 |
||||||||||||||||||||||
|
Target disease: |
Coronary atherosclerotic heart disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
研究艾司氯胺酮能否减轻OPCAB术后炎症反应,改善术后谵妄。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate whether esketamine can reduce the inflammatory response and decrese postoperative delirium after OPCAB |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
选取2024年7月到2024年10月于青岛大学附属医院行择期非体外循环心脏手术的成年患者130例, ASAⅡ~Ⅳ级,手术类型为择期非体外循环冠状动脉旁路移植术。使用电脑随机数字法将患者随机分为术中泵注艾司氯胺酮的艾司氯胺酮组(S组)和术中不泵注艾司氯胺酮的对照组。记录患者术前、术后12h、72h的炎症反应相关指标(CRP、IL-6等),并于术后七天内每天使用CAM-ICU/CAM量表评估患者是否谵妄及谵妄评分。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
A total of 130 adult patients who underwent elective OPCABG in the Affiliated Hospital of Qingdao University from July 2024 to October 2024 were selected for ASA II.~IV. The patients were randomly divided into the esketamine group (S group) and the control group without esketamine during the operation. The inflammatory response related indexes (CRP, IL-6, etc.) were recorded before and 12 hours and 72 hours after surgery, and the CAM-ICU/CAM scale was used every day for seven days after surgery to evaluate whether the patients had delirium and delirium score. |
||||||||||||||||||||||
|
纳入标准: |
1) ASAⅡ~Ⅳ级 2) 年龄大于18岁 3) 行择期非体外循环冠脉旁路移植手术 4) 病人和家属对实验方案内容了解并签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1) ASAII.~IV 2) Be older than 18 years old 3) Elective off-pump coronary artery bypass transplantation 4) Patients and their families understand the content of the experimental protocol and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1) 既往心脏手术史; 2) 既往精神疾病史、抑郁史; 3) 麻醉药禁忌史; 4) 合并贫血、血液疾病或凝血功能异常; 5) 合并严重肝肾功能损伤; 6) 合并感染性疾病; 7) 近期使用糖皮质激素或其他影响炎症反应的药物; 8) 因视听或心理疾病不能配合调查人员者; 9) 酒精或非法药物滥用障碍。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) History of previous cardiac surgery; 2) History of previous mental illness and depression; 3) History of contraindications to anesthetics; 4) Combined with anemia, blood disorders or abnormal coagulation function; 5) Combined with severe liver and kidney impairment; 6) Co-existing infectious diseases; 7) Recent use of glucocorticoids or other drugs that affect the inflammatory response; 8) Those who are unable to cooperate with the investigators due to audio-visual or psychological diseases; 9) Alcohol or illicit drug abuse disorder. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-18 00:00:00至 To 2024-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-07-18 00:00:00 至 To 2024-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
电脑随机数字法 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Computer random number method |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究盲法设计为三盲。研究中,每位患者的分组情况将由一位独立于手术过程的医师进行管理,该医师将负责根据分组情况,将对应的研究药品或生理盐水(对照)放置于患者专属的密封信封中。在手术前,这些信封将被分发给麻醉医师,而这位负责管理分组的研究者将不会参与到患者的麻醉实施或后续的随访工作中。 患者围术期的认知功能评估由接受专业评估训练后的研究医师负责,研究医师在研究全程仅参与认知功能评估,不知晓分组情况。患者术后炎症指标经由独立于手术过程的研究医师收集整理,不知晓分组情况。 整个研究过程中,包括麻醉医师在内的所有直接接触患者的医护人员,以及受试者本人,都不会知晓具体的分组情况和信封内的药物种类。 |
|
Blinding: |
The blinding design of this study is triple-blinded. In the study, the grouping of each patient will be managed by a physician independent of the surgical procedure, who will be responsible for placing the corresponding study drug or saline (control) in a sealed envelope designated for the patient according to the group assignment. Prior to surgery, these envelopes will be distributed to the anesthesiologist, and the researcher responsible for managing the grouping will not participate in the anesthesia administration or subsequent follow-up of the patients. The assessment of patients' perioperative cognitive function will be conducted by research physicians who have received professional training in assessment. These research physicians will only participate in the cognitive function assessment throughout the study and will be unaware of the group assignments. The patients' postoperative inflammatory indicators will be collected and organized by research physicians independent of the surgical procedure, who are also unaware of the group assignments. Throughout the entire study, all healthcare professionals who have direct contact with the patients, including the anesthesiologists, as well as the subjects themselves, will remain unaware of the specific group assignments and the type of drug in the envelopes. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
否 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.病例记录表:患者的麻醉医师将收到纸质版患者病例记录表,记录患者基础信息、基础疾病、术中血管活性药物(去甲肾上腺素、肾上腺素等)用量及围术期出现的不良反应,负责评估认知功能及收集患者炎症指标的研究医师也将会使用纸质版评估表、数据收集表按照患者编号填写相应数据信息。 2.电子采集和管理系统使用ResMan系统进行数据采集和管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form: The anesthesiologists will receive a paper-based CRF, which documents the patient's basic information, underlying diseases, intraoperative dosages of vasoactive drugs (such as norepinephrine and epinephrine), and adverse reactions during the perioperative period. The research physician responsible for assessing cognitive function and collecting inflammatory indicators from the patient will also use paper-based assessment forms and data collection forms to fill in corresponding data according to the patient's ID number. Electronic Data Collection and Management System: The ResMan system is utilized for data collection and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |